NCT07703137Enrolling by invitation

NAD Supplementation in Parkinson's Disease

Neurovascular Coupling, Clinical Outcomes, and NAD Supplementation in Parkinson's Disease

Source: ClinicalTrials.gov · Last updated 12 Aug 2026

Brief summary (registry, in English)

The goal of this clinical trial is to learn whether Nicotinamide Riboside, a form of Vitamin B3 also known as NR, can improve blood vessel health in the brain, memory, and physical function in eligible study participants. NR is considered investigational for this study because it is not yet established for this specific use. The main questions it aims to answer are: Can NR improve non-invasive measures of blood vessel health in the brain? Can NR improve memory testing results and physical function? Researchers will compare participants who receive NR with participants who receive a placebo, an inactive substance that looks like the study drug, to see if NR has beneficial effects. Participants will be randomly assigned to receive either NR or placebo. They will complete 3 study visits over 13 weeks at the Translational Geroscience Laboratory at the University of Oklahoma Health Campus. During the visits, participants will complete questionnaires, memory testing, non-invasive blood vessel measurements, physical function tests, and a blood draw.

Status (registry): Enrolling by invitation
Study type: Interventional
Enrollment: 40 (estimated)
First submitted: 26 Jun 2026
Start date: 10 Aug 2026
Primary completion date: 31 Jul 2027
Lead sponsor: University of Oklahoma
Diseases: Parkinson disease
NCT number: NCT07703137

What you commit to

Study type: Interventional
Planned participants: 40
From 10 Aug 2026 to the primary completion date, 31 Jul 2027
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Cerebrovascular accident other than TIA within 60 days prior to Visit 0.
Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization.

Other illness

Not able to communicate or follow instructions due to aphasia or severe cognitive impairment.
Active CNS disease including multiple sclerosis, uncontrolled seizures, active cancer.
Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse.
Any other medical condition and/or unstable or severe medical illness which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol.

Lab values

Abnormal kidney function (creatinine \>2mg/dL or EGFR \<30mL/min) by most recent labs within 6 months prior to Visit 0.
Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0.

Who the study is looking for

Clinical diagnosis of Parkinson's disease according to Movement Disorder Society clinical diagnostic criteria (59), Hoehn and Yahr stages I-III at enrollment (ON medication state when applicable) (60).
Age ≥55 years at enrollment.
Adequate hearing and visual acuity to participate in the examinations
Ability to provide written informed consent in English.
Ability to complete study procedures, including seated tasks and walking tasks (with or without an assistive device, if needed for safety).
Stable antiparkinsonian medication regimen for ≥4 weeks prior to baseline (or drug-naive).

Age in the registry: 55 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Center for Geroscience and Healthy Brain Aging Coordinator of this site? Confirm its status	Oklahoma City	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.